TIGIT and nonpapillary renal cell carcinoma: Multiple immune checkpoints had significant differences between the high- and low- groups, e.g., CD274 (PD-L1), CTLA4, HAVCR2, LAG3, PDCD1 (PD-1), PDCD1LG2, TIGIT and SIGLECI5, providing potential therapeutic targets for ICB in ccRCC (Figure 6A).